These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 38640156)

  • 1. Assessing Quality of Life, Economic Burden, and Independence Across the Alzheimer's Disease Continuum Using Patient-Caregiver Dyad Surveys.
    Tahami Monfared AA; Khachatryan A; Hummel N; Kopiec A; Martinez M; Zhang R; Zhang Q
    J Alzheimers Dis; 2024; 99(1):191-206. PubMed ID: 38640156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer's Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study.
    Chandler JM; Ye W; Mi X; Doty EG; Johnston JA
    J Alzheimers Dis; 2024; 100(2):563-578. PubMed ID: 38875031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
    Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
    J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study.
    Olazarán J; Agüera-Ortiz L; Argimón JM; Reed C; Ciudad A; Andrade P; Dilla T
    Int Psychogeriatr; 2017 Dec; 29(12):2081-2093. PubMed ID: 28720158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1.
    Robinson RL; Rentz DM; Andrews JS; Zagar A; Kim Y; Bruemmer V; Schwartz RL; Ye W; Fillit HM
    J Alzheimers Dis; 2020; 75(2):437-450. PubMed ID: 32250304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing out-of-pocket expenses and indirect costs for the Alzheimer disease continuum in the United States.
    Monfared AAT; Hummel N; Chandak A; Khachatryan A; Zhang Q
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1065-1077. PubMed ID: 37307097
    [No Abstract]   [Full Text] [Related]  

  • 7. Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS.
    Reed C; Belger M; Scott Andrews J; Tockhorn-Heidenreich A; Jones RW; Wimo A; Dodel R; Haro JM
    Int Psychogeriatr; 2020 Feb; 32(2):267-277. PubMed ID: 31134870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's disease severity and its association with patient and caregiver quality of life in Japan: results of a community-based survey.
    Montgomery W; Goren A; Kahle-Wrobleski K; Nakamura T; Ueda K
    BMC Geriatr; 2018 Jun; 18(1):141. PubMed ID: 29898679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
    Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
    BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caregiver rating bias in mild cognitive impairment and mild Alzheimer's disease: impact of caregiver burden and depression on dyadic rating discrepancy across domains.
    Pfeifer L; Drobetz R; Fankhauser S; Mortby ME; Maercker A; Forstmeier S
    Int Psychogeriatr; 2013 Aug; 25(8):1345-55. PubMed ID: 23651733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing Alzheimer's disease patients' quality of life: Discrepancies between patient and caregiver perspectives.
    Andrieu S; Coley N; Rolland Y; Cantet C; Arnaud C; Guyonnet S; Nourhashemi F; Grand A; Vellas B;
    Alzheimers Dement; 2016 Apr; 12(4):427-37. PubMed ID: 26602086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of the Severity of Alzheimer's Disease on the Quality of Life, Activities of Daily Living, and Caregiving Costs for Institutionalized Patients on Anti-Alzheimer Medications in Japan.
    Ashizawa T; Igarashi A; Sakata Y; Azuma M; Fujimoto K; Kobayashi T; Takase Y; Ikeda S
    J Alzheimers Dis; 2021; 81(1):367-374. PubMed ID: 33780368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between caregivers' global ratings of Alzheimer's disease patients' quality of life, disease severity, and the caregiving experience.
    Karlawish JH; Casarett D; Klocinski J; Clark CM
    J Am Geriatr Soc; 2001 Aug; 49(8):1066-70. PubMed ID: 11555068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative importance of patient disease indicators on informal care and caregiver burden in Alzheimer's disease.
    Bergvall N; Brinck P; Eek D; Gustavsson A; Wimo A; Winblad B; Jönsson L
    Int Psychogeriatr; 2011 Feb; 23(1):73-85. PubMed ID: 20619068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Social-economic costs and quality of life of Alzheimer disease in the Canary Islands, Spain.
    Lopez-Bastida J; Serrano-Aguilar P; Perestelo-Perez L; Oliva-Moreno J
    Neurology; 2006 Dec; 67(12):2186-91. PubMed ID: 17190942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Observation of Patient and Caregiver Burden Associated with Early Alzheimer's Disease in the United States: Design and Baseline Findings of the GERAS-US Cohort Study1.
    Robinson RL; Rentz DM; Bruemmer V; Scott Andrews J; Zagar A; Kim Y; Schwartz RL; Ye W; Fillit HM
    J Alzheimers Dis; 2019; 72(1):279-292. PubMed ID: 31561360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of family caregiver ratings of patient quality of life in Alzheimer disease: cross-sectional results from the Canadian Alzheimer's Disease Quality of Life Study.
    Naglie G; Hogan DB; Krahn M; Black SE; Beattie BL; Patterson C; Macknight C; Freedman M; Borrie M; Byszewski A; Bergman H; Streiner D; Irvine J; Ritvo P; Comrie J; Kowgier M; Tomlinson G
    Am J Geriatr Psychiatry; 2011 Oct; 19(10):891-901. PubMed ID: 21946805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic and caregiver impact of Alzheimer's disease across the disease spectrum: a cohort study.
    Dauphinot V; Potashman M; Levitchi-Benea M; Su R; Rubino I; Krolak-Salmon P
    Alzheimers Res Ther; 2022 Feb; 14(1):34. PubMed ID: 35151368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2022 Alzheimer's disease facts and figures.
    Alzheimers Dement; 2022 Apr; 18(4):700-789. PubMed ID: 35289055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.